ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2177

Class a Scavenger Receptor(SR-a)Exacerbated Synovial Fibroblasts-Mediated Inflammation in Rheumatoid Arthritis

Yingni Li1, Fanlei Hu2, Li Zheng1, Linchong Su3, Lianjie Shi2, Pei Song1 and Zhanguo Li2, 1Peking University People's Hospital, Beijing, China, 2Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 3Hubei Minzu University, Enshi, China

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cytokines, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors

Session Type: Abstract Submissions (ACR)

Background/Purpose Class A scavenger receptor (SR-A/CD204), mainly expressed on macrophages, plays an important role in the pathogenesis of atherosclerosis and in the pattern recognition of pathogen infection. However, its role in rheumatoid arthritis (RA) has not been defined. The aim of this study was to reveal the expression of SR-A in synovial fibroblasts (RASF) and its impact on synovial inflammation.

Methods Immunohistochemistry (IHC) was performed to detect the expression of SR-A in the synovial tissues from RA and osteoarthritis (OA) patients. The expression of SR-A in RASF was demonstrated by both qPCR and western blot. To reveal the effects of SR-A on synovial inflammation, RASF were treated with either recombinant SR-A protein or SR-A specific siRNA. Then, the expression of pro-inflammatory cytokines (TNF-α, IL-6, and IL-8) and MMPs (MMP-1, MMP-3, and MMP-9) were determined by real-time PCR and ELISA. Accordingly, the activation of the MAPKs and NF-κB signaling pathways was evaluated by western blot when SR-A was silenced. 

Results The level of SR-A was higher in the synovial tissues from RA patients than those from OA patients. Moreover, we for the first time demonstrated that SR-A was expressed in RASF. SR-A protein stimulated pro-inflammatory cytokine and MMP expression in RASF. On the contrary, knocking down SR-A by specific siRNA suppressed the expression of these factors, with dampened activation of the ERK, JNK, p38 and NF-κB signaling pathways.

Conclusion SR-A exacerbated synovial inflammation and cartilage erosion in RA. Targeting SR-A might provide novel therapeutic strategies for overcoming this stubborn disease.


Disclosure:

Y. Li,
None;

F. Hu,
None;

L. Zheng,
None;

L. Su,
None;

L. Shi,
None;

P. Song,
None;

Z. Li,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/class-a-scavenger-receptor%ef%bc%88sr-a%ef%bc%89exacerbated-synovial-fibroblasts-mediated-inflammation-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology